Effect of pravastatin on the development of diabetes and adiponectin production


      In the West of Scotland Coronary Prevention Study (WOSCOPS), treatment of hypercholesterolemic men with pravastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, reduced their likelihood to progress to diabetes mellitus by 30%. However, the mechanism of this effect of pravastatin has not been investigated. In the current study, we examined the effect of pravastatin on the development of diabetes in obese diabetic mice, and on the insulin-induced glucose uptake and adiponectin production. Pravastatin treatment attenuated the development of diabetes in db/db and high fat/high sucrose diet-fed C57BL/6J mice. An in vivo glucose transport assay showed that pravastatin upregulated glucose uptake in adipose tissue. Insulin-stimulated glucose uptake was enhanced in primary adipocytes isolated from pravastatin-treated mice. Pravastatin treatment increased adiponectin production in 3T3-L1 adipocytes. Plasma adiponectin levels were significantly increased in pravastatin-treated mice. Analyses of plasma samples from the WOSCOPS biobank indicated a significant increase of plasma adiponectin levels with pravastatin treatment (placebo −0.28 ± 0.34 μg/ml versus pravastatin +1.47 ± 0.33 μg/ml, p = 0.0003). Taken together, our findings suggest that pravastatin may have beneficial effects on adipose tissue, which may partly explain the reduction of the development of diabetes by pravastatin treatment.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • DeFronzo R.A.
        • Ferrannini E
        Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.
        Diab Care. 1991; 14: 173-194
      1. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
        JAMA. 2001; 285: 2486-2497
        • Uusitupa M.I.
        • Niskanen L.K.
        • Siitonen O.
        • Voutilainen E.
        • Pyorala K.
        5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects.
        Circulation. 1990; 82: 27-36
        • Shepherd J.
        • Cobbe S.M.
        • Ford I.
        • et al.
        Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
        N Engl J Med. 1995; 333: 1301-1307
      2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.
        N Engl J Med. 1998; 339: 1349-1357
      3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1994; 344: 1383-1389
        • Takemoto M.
        • Liao J.K.
        Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
        Arterioscler Thromb Vasc Biol. 2001; 21: 1712-1719
        • Ohrvall M.
        • Lithell H.
        • Johansson J.
        • Vessby B.
        A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia.
        Metabolism. 1995; 44: 212-217
        • Jula A.
        • Marniemi J.
        • Huupponen R.
        • et al.
        Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial.
        JAMA. 2002; 287: 598-605
        • Ohmura C.
        • Watada H.
        • Hirose T.
        • Tanaka Y.
        • Kawamori R.
        Acute onset and worsening of diabetes concurrent with administration of statins.
        Endocr J. 2005; 52: 369-372
        • Farrer M.
        • Winocour P.H.
        • Evans K.
        • et al.
        Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures.
        Diabetes Res Clin Pract. 1994; 23: 111-119
        • Sheu W.H.
        • Shieh S.M.
        • Shen D.D.
        • et al.
        Effect of pravastatin treatment on glucose, insulin, and lipoprotein metabolism in patients with hypercholesterolemia.
        Am Heart J. 1994; 127: 331-336
        • Baba T.
        • Kodama T.
        • Yajima Y.
        • Ishizaki T.
        Effects of pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on glucose tolerance in patients with essential hypertension.
        Diab Care. 1993; 16: 402-404
        • Gannage-Yared M.H.
        • Azar R.R.
        • Amm-Azar M.
        • et al.
        Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients.
        Metabolism. 2005; 54: 947-951
        • Nielsen S.
        • Schmitz O.
        • Moller N.
        • et al.
        Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria.
        Diabetologia. 1993; 36: 1079-1086
        • Koh K.K.
        • Quon M.J.
        • Han S.H.
        • et al.
        Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia.
        J Am Coll Cardiol. 2005; 45: 1649-1653
        • Koh K.K.
        • Quon M.J.
        • Han S.H.
        • et al.
        Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients.
        Circulation. 2004; 110: 3687-3692
        • Sonmez A.
        • Baykal Y.
        • Kilic M.
        • et al.
        Fluvastatin improves insulin resistance in nondiabetic dyslipidemic patients.
        Endocrine. 2003; 22: 151-154
        • Paolisso G.
        • Sgambato S.
        • De Riu S.
        • et al.
        Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics.
        Eur J Clin Pharmacol. 1991; 40: 27-31
        • Paolisso G.
        • Barbagallo M.
        • Petrella G.
        • et al.
        Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.
        Atherosclerosis. 2000; 150: 121-127
        • Chan P.
        • Tomlinson B.
        • Lee C.B.
        • Pan W.H.
        • Lee Y.S.
        Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects.
        Hypertension. 1996; 28: 647-651
        • Okada K.
        • Maeda N.
        • Kikuchi K.
        • et al.
        Pravastatin improves insulin resistance in dyslipidemic patients.
        J Atheroscler Thromb. 2005; 12: 322-329
        • Guclu F.
        • Ozmen B.
        • Hekimsoy Z.
        • Kirmaz C.
        Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome.
        Biomed Pharmacother. 2004; 58: 614-618
        • Maeda K.
        • Okubo K.
        • Shimomura I.
        • et al.
        cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1).
        Biochem Biophys Res Commun. 1996; 221: 286-289
        • Maeda N.
        • Shimomura I.
        • Kishida K.
        • et al.
        Diet-induced insulin resistance in mice lacking adiponectin/ACRP30.
        Nat Med. 2002; 8: 731-737
        • Matsuda M.
        • Shimomura I.
        • Sata M.
        • et al.
        Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis.
        J Biol Chem. 2002; 277: 37487-37491
        • Sakamoto K.
        • Sakamoto T.
        • Ogawa H.
        The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study.
        Clin Ther. 2006; 28: 1012-1021
        • Shetty G.K.
        • Economides P.A.
        • Horton E.S.
        • Mantzoros C.S.
        • Veves A.
        Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes.
        Diab Care. 2004; 27: 2450-2457
        • Freeman D.J.
        • Norrie J.
        • Sattar N.
        • et al.
        Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.
        Circulation. 2001; 103: 357-362
        • Rossmeisl M.
        • Rim J.S.
        • Koza R.A.
        • Kozak L.P.
        Variation in type 2 diabetes—related traits in mouse strains susceptible to diet-induced obesity.
        Diabetes. 2003; 52: 1958-1966
        • Rodbell M.
        Metabolism of Isolated Fat Cells. I: Effects of hormones on glucose metabolism and, lipolysis.
        J Biol Chem. 1964; 239: 375-380
        • Halperin M.L.
        • Cheema-Dhadli S.
        Comparison of glucose and fructose transport into adipocytes of the rat.
        Biochem J. 1982; 202: 717-721
        • Furukawa S.
        • Fujita T.
        • Shimabukuro M.
        • et al.
        Increased oxidative stress in obesity and its impact on metabolic syndrome.
        J Clin Invest. 2004; 114: 1752-1761
        • Berg A.H.
        • Combs T.P.
        • Du X.
        • Brownlee M.
        • Scherer P.E.
        The adipocyte-secreted protein Acrp30 enhances hepatic insulin action.
        Nat Med. 2001; 7: 947-953
        • Yamauchi T.
        • Kamon J.
        • Waki H.
        • et al.
        The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.
        Nat Med. 2001; 7: 941-946
        • Weisberg S.P.
        • McCann D.
        • Desai M.
        • et al.
        Obesity is associated with macrophage accumulation in adipose tissue.
        J Clin Invest. 2003; 112: 1796-1808
        • Roth J.
        • Qiang X.
        • Marban S.L.
        • Redelt H.
        • Lowell B.C.
        The obesity pandemic: where have we been and where are we going?.
        Obes Res. 2004; 12: 88S-101S
        • Di Gregorio G.B.
        • Yao-Borengasser A.
        • Rasouli N.
        • et al.
        Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone.
        Diabetes. 2005; 54: 2305-2313
        • Zelvyte I.
        • Dominaitiene R.
        • Crisby M.
        • Janciauskiene S.
        Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro.
        Pharmacol Res. 2002; 45: 147-154
        • Spranger J.
        • Kroke A.
        • Mohlig M.
        • et al.
        Adiponectin and protection against type 2 diabetes mellitus.
        Lancet. 2003; 361: 226-228
        • Okamoto Y.
        • Kihara S.
        • Ouchi N.
        • et al.
        Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice.
        Circulation. 2002; 106: 2767-2770
        • Hirose H.
        • Kawai T.
        • Yamamoto Y.
        • et al.
        Effects of pioglitazone on metabolic parameters, body fat distribution and serum adiponectin levels in Japanese male patients with type 2 diabetes.
        Metabolism. 2002; 51: 314-317
        • Yang W.S.
        • Jeng C.Y.
        • Wu T.J.
        • et al.
        Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients.
        Diab Care. 2002; 25: 376-380
        • Kubota N.
        • Terauchi Y.
        • Kubota T.
        • et al.
        Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways.
        J Biol Chem. 2006; 281: 8748-8755
        • Wong V.
        • Stavar L.
        • Szeto L.
        • et al.
        Atorvastatin induces insulin sensitization in Zucker lean and fatty rats.
        Atherosclerosis. 2006; 184: 348-355
        • Suzuki M.
        • Kakuta H.
        • Takahashi A.
        • et al.
        Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice.
        J Atheroscler Thromb. 2005; 12: 77-84